Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly

被引:39
作者
Wasil, T
Lichtman, SM
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Commack, NY 11725 USA
[2] Long Isl Jewish Med Ctr, Div Oncol, New York, NY USA
关键词
elderly; pharmacology; toxicity; chemotherapy;
D O I
10.1634/theoncologist.10-8-602
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Persons over the age of 65 years are the fastest growing segment of the U.S.population. In the next 30 years, they will comprise more than 20% of the population. Fifty percent of all cancers occur in this age group, and therefore, there is an expected rise in the total cancer burden. Data are becoming available that will better guide the use of chemotherapy in the older patient population. In this paper, information regarding age-related physiologicchanges and their relationship to pharmacology, functional status, and hematopoiesis is presented. The adjuvant treatment of breast and colon cancer, as well as the primary therapy of aggressive non-Hodgkin lymphoma is reviewed. The treatment of more advanced breast, ovarian, and non-small cell lung cancer is also discussed.
引用
收藏
页码:602 / 612
页数:11
相关论文
共 155 条
[1]  
Abe O, 1998, LANCET, V352, P930
[2]   PREVALENCE OF ANEMIA IN MEDICAL-PRACTICE - COMMUNITY VERSUS REFERRAL PATIENTS [J].
ANIA, BJ ;
SUMAN, VJ ;
FAIRBANKS, VF ;
MELTON, LJ .
MAYO CLINIC PROCEEDINGS, 1994, 69 (08) :730-735
[3]   Incidence of anemia in older people: An epidemiologic study in a well defined population [J].
Ania, BJ ;
Suman, VJ ;
Fairbanks, VF ;
Rademacher, DM ;
Melton, LJ .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1997, 45 (07) :825-831
[4]   Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly [J].
Aparicio, T ;
Desramé, J ;
Lecomte, T ;
Mitry, E ;
Belloc, J ;
Etienney, I ;
Montembault, S ;
Vayre, L ;
Locher, C ;
Ezenfis, J ;
Artru, P ;
Mabro, M ;
Dominguez, S .
BRITISH JOURNAL OF CANCER, 2003, 89 (08) :1439-1444
[5]   Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy [J].
Argiris, A ;
Li, Y ;
Murphy, BA ;
Langer, CJ ;
Forastiere, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) :262-268
[6]   Topotecan dosing guidelines in ovarian cancer: Reduction and management of hematologic toxicity [J].
Armstrong, DK .
ONCOLOGIST, 2004, 9 (01) :33-42
[7]   Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women [J].
Bajetta, E ;
Procopio, G ;
Celio, L ;
Gattinoni, L ;
Della Torre, S ;
Mariani, L ;
Catena, L ;
Ricotta, R ;
Longarini, R ;
Zilembo, N ;
Buzzoni, R .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2155-2161
[8]  
Baker SD, 1997, CLIN GERIATR MED, V13, P169
[9]   Patients aged ≤ 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy [J].
Balducci, L ;
Lyman, GH .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1583-1584
[10]   Increased risk of myelotoxicity in elderly patients with non-hodgkin lymphoma - The case for routine prophylaxis with colony-stimulating factor beginning in the first cycle of chemotherapy [J].
Balducci, L ;
Repetto, L .
CANCER, 2004, 100 (01) :6-11